405939-28-8

Basic information

• Product Name: (4-IODO-PYRIDIN-2-YL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (4-IODO-PYRIDIN-2-YL)-CARBAMIC ACID TERT-BUTYL ESTER;TERT-BUTYL (4-IODOPYRIDIN-2-YL)CARBAMATE;2-Boc-amino-4-iodopyridine;CARBAMICACID,(4-IODO-2-PYRIDINYL)-,1,1DIMETHYLETHYLESTER
• CAS NO: 405939-28-8
• Molecular Formula: C₁₀H₁₃IN₂O₂
• Molecular Weight: 320.13
• Product Categories: pharmacetical
• Mol File: 405939-28-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 158-158.5°C
• Boiling Point: 321 °C at 760 mmHg
• Flash Point: 147.9 °C
• Appearance: /
• Density: 1.652 g/cm³
• Vapor Pressure: 0.000307mmHg at 25°C
• Refractive Index: 1.609
• CAS DataBase Reference: (4-IODO-PYRIDIN-2-YL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (4-IODO-PYRIDIN-2-YL)-CARBAMIC ACID TERT-BUTYL ESTER(405939-28-8)
• EPA Substance Registry System: (4-IODO-PYRIDIN-2-YL)-CARBAMIC ACID TERT-BUTYL ESTER(405939-28-8)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 405939-28-8(Hazardous Substances Data)

Usage

General Description

"(4-IODO-PYRIDIN-2-YL)-CARBAMIC ACID TERT-BUTYL ESTER" is a complex organic chemical compound with significant utility in chemical synthesis and pharmaceutical research. It is also known by its CAS number, 1607829-92-2. (4-IODO-PYRIDIN-2-YL)-CARBAMIC ACID TERT-BUTYL ESTER falls under the category of carbamic acids and among its key features are a pyridine ring, an iodine atom, and a tert-butyl ester group. The iodine atom and the pyridine ring, acting as functional groups, allow it to easily participate in various reactions, making it a valuable intermediate in the synthesis of more complex compounds. As such, it plays an instrumental role in the fields of medicinal chemistry, drug design, and material science.

InChI:InChI=1/C10H13IN2O2/c1-10(2,3)15-9(14)13-8-6-7(11)4-5-12-8/h4-6H,1-3H3,(H,12,13,14)

Upstream product

• 405939-79-9 4-iodo-2-nicotinic acid 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 1375500-39-2 {4-[2-(2-methoxy-phenyl)-ethyl]-pyridin-2-yl}-urea 
• 1375501-68-0 1-benzoyl-3-{4-[2-(2-methoxy-phenyl)-ethyl]-pyridin-2-yl}-urea 
• 1375501-66-8 4-[2-(2-methoxy-phenyl)-ethyl]-pyridin-2-ylamine 
• 1375501-64-6 {4-[2-(2-methoxy-phenyl)-ethyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 1375501-61-3 [4-(2-methoxy-phenylethynyl)-pyridin-2-yl]-carbamic acid tert-butyl ester 
• 652153-43-0 [4-(2-{tert-butoxycarbonyl-[3-(tert-butyl-dimethyl-silanyloxy)-propyl]-amino}-pyridin-4-yl)-[1,3,5]triazin-2-yl]-(3-chloro-phenyl)-carbamic acid tert-butyl ester 
• 652153-35-0 3-((4-(4-((3-chlorophenyl)amino)-1,3,5-triazin-2-yl)-2-pyridinyl)amino)-1-propanol 
• 690258-25-4 7-iodo-[1,2,4]triazolo[1,5-a]pyridine 
• 552331-00-7 4-(iodo)pyridin-2-amine 
• 622402-25-9 tert-butyl (4-phenylpyridin-2-yl)carbamate 
• 201810-33-5 tert-butyl (4-(4-formylphenyl)pyridin-2-yl)carbamate 
• 622402-28-2 7-phenyl-3-pyridin-4-yl-imidazo[1,2-a]pyridine 
• 622402-36-2 4-(3-iodo-imidazo[1,2-a]pyridin-7-yl)-benzaldehyde 
• 622402-26-0 3-iodo-7-phenyl-imidazo[1,2-a]pyridine 

Relevant articles and documents

(2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1, 2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: A selective α-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

A series of β-substituted biarylphenylalanine amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the metabolic profile of early analogues led to the discovery of (2S

Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors

On the basis of previous studies, we identified pyrazine-pyridine A as a potent vascular endothelial growth factor inhibitor and pyrimidine-pyridine B as a moderately potent cyclin dependent kinase (CDK) inhibitor. A proposed combination of CGP-60474 and

SUBSTITUTED TRIAZINE KINASE INHIBITORS

The present invention provides substituted 1,3,5-triazine compounds as kinase inhibitors and a method for treating or ameliorating a kinase mediated disorder.